BrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration

New data released by BrainStorm Cell Therapeutics has revealed promising results for their ALS treatment, NurOwn. The Phase 3 trial showcased a significant reduction in the neurodegeneration biomarker, NfL, among participants who received NurOwn compared to those who were given a placebo. The decision to analyze biomarker data was influenced by recent FDA approvals for ALS drugs and the correlat..